

ASX Announcement

Regeneus Share Purchase Plan closes oversubscribed

Sydney, Australia – 9 September 2014

Regeneus Ltd (ASX: RGS) is pleased to announce that it has successfully achieved its target of raising A\$3m through its Share Purchase Plan (**SPP or the Plan**) offered to shareholders. This now completes the second part of the company's A\$6m raising announced to the market on 8 August 2014.

The SPP closed oversubscribed by 10% and the Directors have resolved to accept the oversubscriptions in recognition of the strong show of support by shareholders. Regeneus Chairman John Martin, said, "we have been very encouraged by our shareholders response to the SPP. This follows on from the support shown by institutions and sophisticated investors in the recent placement".

On 15 August 2014, the company announced that it had successfully completed a A\$3m private placement with institutional and sophisticated investors.

Under the SPP, shareholders were invited to subscribe for up to \$15,000 of new Regeneus ordinary shares at an issue price of \$0.26c. The company will allot the new shares on Thursday 11 September 2014 and these shares will commence trading on ASX on Friday 12 September 2014.

The funds raised together with the R&D tax rebate for FY14 of \$3.7m and sales revenues means the company has sufficient funds to accelerate the product development initiatives outlined in the announcement of 8 August.

ENDS

About Regeneus:

Regeneus Ltd (ASX: RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient's cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.

Regeneus' lead product for the veterinary health market is CryoShot, a clinical stage allogeneic adipose stem cell product for the treatment of canine and equine OA. CryoShot canine is scheduled for a US registration trial in Q4 2015. Regeneus has a clinical stage autologous therapeutic cancer vaccine, Kvax, which will commence marketing trials in the US and Australia in Q4 2014. The company has also acquired in July 2014 the exclusive rights to commercialise the vaccine technology for human applications and plans to commence a first-in-man study in Q1 2015.

Contact and further information:

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au